Xcounter Share Discussion Threads

[buystock] 22/1/2010 15:38

NOT ME SON.ANOTHER 2 HOLDING RNS STATEMENTS filling up before news on tuesday.

[argy2] 22/1/2010 14:31

buystock

Good to see you kicked off the Sharecrazy thread.

[buystock] 22/1/2010 12:15

Co-development of the breast CT scanner provides a cost effective way for XCounter to progress the

development of the detector technology as, under the current proposals, Artemis intends to provide €1.75m

over a period of two years during the R&D phase of the project. Artemis would fund XCounter's detector

development in return for exclusivity for the PCT technology in the Mammo CT application.

Artemis has applied for a €2.8m grant from the German government (Bundesministerium für Bildung und

Forschung) to fund half of the project. It is currently anticipated that the German government will announce

the results of the grant application on or around 26 January 2010.

If Artemis' application for the grant is successful, the Company anticipates negotiating and signing a co-

development agreement with Artemis in the first quarter of 2010 which will include provisions granting

Artemis exclusivity for the PCT technology for the Mammo CT application. Following the developmental

phase, Artemis proposes to licence the product to a major OEM and it is XCounter's current intention at that

time to enter into a supply agreement with Artemis, so as to exclusively manufacture and supply the detector

components to be integrated into the completed Mammo CT device.

The Directors believe that the total initial market for the complete Mammo

CT systems to be €150m per annum.22/01/2010 11:48:30 8.50 29,148 O 2,477.58

22/01/2010 11:05:07 8.50 50,000 O 4,250.00

22/01/2010 11:03:09 8.50 50,000 O 4,250.00

22/01/2010 10:59:26 8.50 8,312 O 706.52

[buystock] 22/1/2010 12:12

22/01/2010 11:48:30 8.50 29,148 O 2,477.58
22/01/2010 11:05:07 8.50 50,000 O 4,250.00
22/01/2010 11:03:09 8.50 50,000 O 4,250.00
22/01/2010 10:59:26 8.50 8,312 O 706.52

[buystock] 22/1/2010 11:43

BUYING BEGINS 22/01/2010 11:05:07 8.50 50,000 O 4,250.00
22/01/2010 11:03:09 8.50 50,000 O 4,250.00
22/01/2010 10:59:26 8.50 8,312 O 706.52

[buystock] 22/1/2010 10:50

NOW ONLY DAYS AWAY TGT 30-40p 2.8m grant by german government we have 3 members on the grant commitee by the 26th jan more than the current mkt cap a sleeping giant 260p highs/funding resolved 2 instititional investers and new commercial partners subscribed for stock. It is a snapshot of the page as it appeared on 22 Dec 2009 17:28:35 GMT PCT Development
XCounter aims to develop a PCT detector which the Directors believe is key to the provision of low
radiation dose and high image quality scanning. The Company aims to develop a sustainable and simple but
robust detector, which delivers high sensitivity and energy resolution, fulfilling the requirements for many
X-ray imaging applications, as well as delivering a high frame rate that would allow for fast image
recognition.
Medical applications
As announced on 2 July 2009, the Company is working with Artemis, a spinoff of
the University of Erlangen's Institute of Medical Physics, under the leadership of Prof. Willi Kalender, to
collaborate on the research and development of the PCT platform in the Mammo CT area for low dose
3D X-ray CT-imaging for breast cancer detection. The Directors believe that the new device which is
intended to result from this collaboration may have the potential to offer more comprehensive and higher
quality breast scanning facilitating earlier detection of breast cancer, the most common form of cancer found
in women.
Artemis and its founder, Prof. Kalender, have substantial expertise and a proven track record in CT physics,
system and applications development. It intends to develop, validate, clinically test and commercialize a
low-dose, high-resolution breast CT scanner using the XCounter photon counting digital direct conversion
solid state detector technology.
Co-development of the breast CT scanner provides a cost effective way for XCounter to progress the
development of the detector technology as, under the current proposals, Artemis intends to provide €1.75m
over a period of two years during the R&D phase of the project. Artemis would fund XCounter's detector
development in return for exclusivity for the PCT technology in the Mammo CT application.
Artemis has applied for a €2.8m grant from the German government (Bundesministerium für Bildung und
Forschung) to fund half of the project. It is currently anticipated that the German government will announce
the results of the grant application on or around 26 January 2010.
If Artemis' application for the grant is successful, the Company anticipates negotiating and signing a co-
development agreement with Artemis in the first quarter of 2010 which will include provisions granting
Artemis exclusivity for the PCT technology for the Mammo CT application. Following the developmental
phase, Artemis proposes to licence the product to a major OEM and it is XCounter's current intention at that
time to enter into a supply agreement with Artemis, so as to exclusively manufacture and supply the detector
components to be integrated into the completed Mammo CT device.
The Directors believe that the total initial market for the complete Mammo
CT systems to be €150m per annum

[buystock] 22/1/2010 06:20

a reply 2 my posts on the lse this will be massively pIMO... it is true what you say... it is not far off... the dates you mention coincide with what i seem to be digging up.. the German government was amongst the first to protect their country from a deeper rescission. Lending and supporting thier companies is something a friend of mine told me is very common. He too is German citizen and runs 4 business's.. ranging from a property lettings agency to an off license and says that he had to pay a 0.05% sum as a form of application in 1998 ( which was the most recent time he had applied) of the sum he had looked to be borrowing, and also believes the same still applies. So with this in mind Artemis would have had to shell out a small fortune to some, in order to gain the grant. He also explained its a process that takes a small amount of time and effort, involving accountants and company draft's and forecast's, also plan's on how the money will be used and spent. Meaning Artemis would have already done this which is time, effort and cost, and a company like this with the resources it has to me, doesn't seem like they would waste time applying for a grant when going to the banks for a lender is far easyier and simpler. Being a medical company this gives more of a chance of obtaining the grant, and also some sort of negotiated grant at worst. So i do see this happening and quick. I also believe that Any take over will happen after the grant has been obtained, and only half the company would go as have the shares now belong to the directors, other investors and even staff member's who cannot sell till they leave, if im correct? if was to be offered 50p+ for each share i own, i'd be happy enough, but would be disappointed not to be here for the bigger pay day.. it will be intresting to see what happens apon grant approval and then on the start of the R&D phase.. which i believe may be almost instant, seem to me there is a lot to look forward to over the next 10 or so trading days and even over the next 1-3 years... but short term this has the potential to become one of those share that people see have a 3-400% jump in an instant and start to get involved... im sure ill be proved to be right.. Ive tried tipping this to 3 or 4 people, but there not interested in something new.. Again i strongly credit you on a great find.. And seems i will owe you a drink very soon... Just to add i think the 2 trades i have placed here of around 21-22 thousand shares, should show tomorrow... Hargreaves landsdown show the market cap at over 7 mio... so i think also the new share will show tomorrow and see a small rise in anticipation of the week/s ahead.. As alwas your thoughts and anyone else's welcome.. Look forward to reading a morning post tomorrow.opular very very soon.

[buystock] 22/1/2010 05:34

rewarded very soon and a new trading level 2.8m+artemis signing up for a licence/oem.

[buystock] 20/1/2010 16:01

grant news get ready for website updating imminent

[buystock] 20/1/2010 15:35

only days now then watch this baby fly 2.8m grant by german government we have 3 members on the grant commitee by the 26th jan more than the current mkt cap a sleeping giant 260p highs/funding resolved 2 instititional investers and new commercial partners subscribed for stock. It is a snapshot of the page as it appeared on 22 Dec 2009 17:28:35 GMT PCT Development
XCounter aims to develop a PCT detector which the Directors believe is key to the provision of low
radiation dose and high image quality scanning. The Company aims to develop a sustainable and simple but
robust detector, which delivers high sensitivity and energy resolution, fulfilling the requirements for many
X-ray imaging applications, as well as delivering a high frame rate that would allow for fast image
recognition.
Medical applications
As announced on 2 July 2009, the Company is working with Artemis, a spinoff of
the University of Erlangen's Institute of Medical Physics, under the leadership of Prof. Willi Kalender, to
collaborate on the research and development of the PCT platform in the Mammo CT area for low dose
3D X-ray CT-imaging for breast cancer detection. The Directors believe that the new device which is
intended to result from this collaboration may have the potential to offer more comprehensive and higher
quality breast scanning facilitating earlier detection of breast cancer, the most common form of cancer found
in women.
Artemis and its founder, Prof. Kalender, have substantial expertise and a proven track record in CT physics,
system and applications development. It intends to develop, validate, clinically test and commercialize a
low-dose, high-resolution breast CT scanner using the XCounter photon counting digital direct conversion
solid state detector technology.
Co-development of the breast CT scanner provides a cost effective way for XCounter to progress the
development of the detector technology as, under the current proposals, Artemis intends to provide €1.75m
over a period of two years during the R&D phase of the project. Artemis would fund XCounter's detector
development in return for exclusivity for the PCT technology in the Mammo CT application.
Artemis has applied for a €2.8m grant from the German government (Bundesministerium für Bildung und
Forschung) to fund half of the project. It is currently anticipated that the German government will announce
the results of the grant application on or around 26 January 2010.
If Artemis' application for the grant is successful, the Company anticipates negotiating and signing a co-
development agreement with Artemis in the first quarter of 2010 which will include provisions granting
Artemis exclusivity for the PCT technology for the Mammo CT application. Following the developmental
phase, Artemis proposes to licence the product to a major OEM and it is XCounter's current intention at that
time to enter into a supply agreement with Artemis, so as to exclusively manufacture and supply the detector
components to be integrated into the completed Mammo CT device.
The Directors believe that the total initial market for the complete Mammo
CT systems to be €150m per annum.

[barrywhit] 20/1/2010 11:25

on the 15th there was also a 100k sell @ 7p........so not all buys.....

[buystock] 20/1/2010 10:23

all buys 20/01/2010 09:38:50 8.50 12,000 O 1,020.00
19/01/2010 08:08:40 8.50 21,443 O 1,822.66
18/01/2010 14:29:04 9.00 29,358 O 2,642.22
18/01/2010 10:31:49 9.00 5,417 O 487.53
18/01/2010 08:04:15 9.00 10,923 O 983.07
15/01/2010 15:18:48 6.00 26,425 O 1,585.50
15/01/2010 14:51:56 9.00 55,062 O 4,955.58
15/01/2010 10:53:49 9.00 5,417 O 487.53
15/01/2010 10:40:31 9.00 5,555 O 499.95
15/01/2010 10:38:43 9.00 10,000 O 900.00
14/01/2010 12:35:35 8.00 7,307 O 584.56
14/01/2010 12:30:17 8.00 1,875 O 150.00
14/01/2010 12:27:01 8.00 466 O 37.28
14/01/2010 12:18:39 8.00 4,365 O 349.20
14/01/2010 11:48:42 8.00 5,000 O 400.00
14/01/2010 11:48:18 8.00 5,000 O 400.00
14/01/2010 11:22:24 8.00 5,000 O 400.00
14/01/2010 10:53:20 8.00 1,244 O 99.52
14/01/2010 10:49:04 7.90 5,517 O 435.84
14/01/2010 09:44:27 7.50 20,000 O 1,500.00
14/01/2010 08:39:17 7.50 3,880 O 291.00
12/01/2010 13:42:20 7.50 6,666 O 499.95
12/01/2010 13:11:22 7.50 1,525 O 114.3

[buystock] 20/1/2010 07:25

grant news very very close and ARTEMIS agreement.hold tight a new day dawn190p rose too 280p on admission with no products on the mkt now have 54 wake up guys buys on plus but limited stock
floatation 55m mkt cap 3 years ago now have over 54 products many on the commercial mkt medical/industrial/vetinary the list goes on law firm Bird & Bird has been advising new client, XCounter AB (publ), on its admission to trading on AIM and institutional placing. XCounter, set up by an ex-NASA scientist, is a Swedish based company that has developed a fundamentally novel technology for capturing 3D digital x-ray images. The placing raised £16 million for the Company giving it a market capitalisation of £55.6 million on admission. XCounter is currently the only Swedish registered company to be admitted to trading on AIM.

Bird & Bird was the lead legal advisor on this deal with lawyers in the firm's UK office involved in all aspects of the deal. London partner Matt Dennis led the work with Mark Cummings as lead assistant. The deal is part of a growing area of work for Bird & Bird in advising non-UK companies wishing to be admitted to AIM. The firm recently acted on AIM admissions for the first Dutch company (Bateman Engineering) and the first Italian company (Teleunit S.A) to launch on AIM.

Commenting on the deal, Johan Stuart, CFO of XCounter said:

"This is the first time we have used Bird & Bird in London and we were delighted with their support".

Matt Dennis added:

"Our corporate work in life sciences is going from strength to strength. This transaction was a great example of our international work in one of our key industry sectors".

For more information contact Natalie Arestis, PR Manager on 020 7905 6248 or s

[buystock] 20/1/2010 06:09

About XCounter
XCounter is an innovation and development house for the leading X-ray companies. XCounter offers ready-to-market imaging systems based on unique 3D technologies. The Company was founded in 1997 by researchers with NASA and CERN experience in space research. It is listed on the London Stock Exchange's AIM market. XCounter is based in Stockholm, Sweden. XCounter's unique and proprietary technology for 3-dimensional X-ray imaging, XCT -3T, has a number of advantages over competing technologies. XCT -3T enables fast acquisition of high resolution 3D images, at low levels of radiation dose. This means more predictable diagnosis as well lower risks for the patients when compared to existing imaging techniques. XCounter currently has four product platforms in development based on XCT -3T, XCounter's unique technology. The first is XC Mammo -3T, the only system originally designed for 3D breast cancer screening. Secondly the XC MP -3T for general body imaging, which is introducing low dose 3D imaging in to general X-ray imaging and preventive cancer screening. Building on the existing technology which it has developed for XC Mammo -3T, XCounter is also developing two platforms for preventive cardiac imaging. XC Cardio -3T for functional imaging of the heart which will have the capability of imaging the perfusion of blood through the heart muscle, leakage through the valves and blood flow through coronary arteries in different phases of the heart cycle. These capabilities will give information enabling the doctor to take medical measures before any serious complications occur. The heart is a very dynamic organ, and many of the heart diseases are best visualized dynamically and our product platform XC Cardio -4T seeks to introduce a totally new dimension by imaging 3D movies of the beating heart. We believe XC Cardio -4T is a solution to a medical need, which none of the leading X-ray companies to date has been able to satisfactorily address. The XCT -3T based product platforms described above address the major part of the US$7 billion digital X-ray system market, and have the potential to expand the market through the introduction of novel low-dose screening applications. More information and our press releases can be accessed at www.XCounter.se.

[buystock] 20/1/2010 06:07

STILL only 9-11% in free float placing shares taken up our imminent prof/new industrial partner/ARTEMIS.Artemis and its founder, Prof. Kalender, have substantial expertise and a proven track record in CT physics, system and applications development. It intends to develop, validate, clinically test and commercialize a low-dose, high-resolution breast CT scanner using the XCounter photon counting digital direct conversion solid state detector technology.


Co-development of the breast CT scanner provides a cost effective way for XCounter to progress the development of the detector technology as, under the current proposals, Artemis intends to provide €1.75m over a period of two years during the R&D phase of the project. Artemis would fund XCounter's detector development in return for exclusivity for the PCT technology in the Mammo CT application.


Artemis has applied for a €2.8m grant from the German government (Bundesministerium für Bildung und Forschung) to fund half of the project. It is currently anticipated that the German government will announce the results of the grant application on or around 26 January 2010.


If Artemis' application for the grant is successful, the Company anticipates negotiating and signing a co-development agreement with Artemis in the first quarter of 2010 which will include provisions granting Artemis exclusivity for the PCT technology for the Mammo CT application. Following the developmental phase, Artemis proposes to licence the product to a major OEM and it is XCounter's current intention at that time to enter into a supply agreement with Artemis, so as to exclusively manufacture and supply the detector components to be integrated into the completed Mammo CT device. AJAT profit making The AJAT acquisition has exceeded the Board's expectations regarding profit and is in line with expectations for revenues in the first six months since completion. Exciting new orders, especially within industrial applications, strengthens the Group's business pipeline in both the short and medium term.


In the 12 months ended 31 August 2009, AJAT reported operating profit of €414,000 (unaudited) and total revenues of approximately €3.5m (unaudited). These revenues came largely from dental and industrial applications. AJAT's detectors are integrated by OEMs in different system applications, spanning from dental panoramic cephalometry, and 2D and future 3D medical imaging. In addition, since its launch in August 2008, AJAT's dental 2D end-user system "Art Plus" has sold 86 units.


AJAT is a profitable business with high growth opportunities within its core dental applications but also within the field of industrial applications such as inspection systems for food production, inspections of welds for the oil and gas piping industry and small animal imaging for the pharmaceutical industry. The Directors believe that AJAT will generate revenues of €4 million and EBITDA of approximately €550,000 (14 per cent. of sales) during the 12 months ending 31 December 2009, a 13 per cent. increase on revenues for the 12 months ended 31 December 2008.

[barrywhit] 19/1/2010 15:54

47million shares bought to the table today, no wonder they dropped the offer....good medium to long-term hold........imho

[buystock] 19/1/2010 05:32

anymore buying we should start moving news anyday now more news in the pipeline Imaging technology
Superior 3D Imaging Technology
XCounter has developed groundbreaking technology for capturing digital X-ray images. This platform technology enables high resolution 3D imaging at low radiation dose to the patient.

» Watch tomosynthesis cine movie and a major oem from ARTEMIS 2.8m grant by german government we have 3 members on the grant commitee by the 26th jan more than the current mkt cap a sleeping giant 260p highs/funding resolved 2 instititional investers and new commercial partners subscribed for stock. It is a snapshot of the page as it appeared on 22 Dec 2009 17:28:35 GMT PCT Development
XCounter aims to develop a PCT detector which the Directors believe is key to the provision of low
radiation dose and high image quality scanning. The Company aims to develop a sustainable and simple but
robust detector, which delivers high sensitivity and energy resolution, fulfilling the requirements for many
X-ray imaging applications, as well as delivering a high frame rate that would allow for fast image
recognition.
Medical applications
As announced on 2 July 2009, the Company is working with Artemis, a spinoff of
the University of Erlangen's Institute of Medical Physics, under the leadership of Prof. Willi Kalender, to
collaborate on the research and development of the PCT platform in the Mammo CT area for low dose
3D X-ray CT-imaging for breast cancer detection. The Directors believe that the new device which is
intended to result from this collaboration may have the potential to offer more comprehensive and higher
quality breast scanning facilitating earlier detection of breast cancer, the most common form of cancer found
in women.
Artemis and its founder, Prof. Kalender, have substantial expertise and a proven track record in CT physics,
system and applications development. It intends to develop, validate, clinically test and commercialize a
low-dose, high-resolution breast CT scanner using the XCounter photon counting digital direct conversion
solid state detector technology.
Co-development of the breast CT scanner provides a cost effective way for XCounter to progress the
development of the detector technology as, under the current proposals, Artemis intends to provide €1.75m
over a period of two years during the R&D phase of the project. Artemis would fund XCounter's detector
development in return for exclusivity for the PCT technology in the Mammo CT application.
Artemis has applied for a €2.8m grant from the German government (Bundesministerium für Bildung und
Forschung) to fund half of the project. It is currently anticipated that the German government will announce
the results of the grant application on or around 26 January 2010.
If Artemis' application for the grant is successful, the Company anticipates negotiating and signing a co-
development agreement with Artemis in the first quarter of 2010 which will include provisions granting
Artemis exclusivity for the PCT technology for the Mammo CT application. Following the developmental
phase, Artemis proposes to licence the product to a major OEM and it is XCounter's current intention at that
time to enter into a supply agreement with Artemis, so as to exclusively manufacture and supply the detector
components to be integrated into the completed Mammo CT device.
The Directors believe that the total initial market for the complete Mammo
CT systems to be €150m per annum.

[buystock] 18/1/2010 14:55

buying is increasing 18/01/2010 14:29:04 9.00 29,358 O 2,642.22
18/01/2010 10:31:49 9.00 5,417 O 487.53
18/01/2010 08:04:15 9.00 10,923 O 983.07
15/01/2010 15:18:48 6.00 26,425 O 1,585.50
15/01/2010 14:51:56 9.00 55,062 O 4,955.58
15/01/2010 10:53:49 9.00 5,417 O 487.53
15/01/2010 10:40:31 9.00 5,555 O 499.95
15/01/2010 10:38:43 9.00 10,000 O 900.00
14/01/2010 12:35:35 8.00 7,307 O 584.56
14/01/2010 12:30:17 8.00 1,875 O 150.00
14/01/2010 12:27:01 8.00 466 O 37.28
14/01/2010 12:18:39 8.00 4,365 O 349.20
14/01/2010 11:48:42 8.00 5,000 O 400.00
14/01/2010 11:48:18 8.00 5,000 O 400.00
14/01/2010 11:22:24 8.00 5,000 O 400.00
14/01/2010 10:53:20 8.00 1,244 O 99.52
14/01/2010 10:49:04 7.90 5,517 O 435.84
14/01/2010 09:44:27 7.50 20,000 O 1,500.00
14/01/2010 08:39:17 7.50 3,880 O 291.00
12/01/2010 13:42:20 7.50 6,666 O 499.95
12/01/2010 13:11:22 7.50 1,525 O 114.38
08/01/2010 10:44:58 7.50 10,000 O 750.00

[buystock] 18/1/2010 12:22

a couple of nibbles on plus but news this month will see us trading @multiples of current share price

[buystock] 18/1/2010 05:14

interest should start building on holding rns news and more news this month from 3/4 different sources

[buystock] 17/1/2010 06:03

more news in the pipeline Imaging technology
Superior 3D Imaging Technology
XCounter has developed groundbreaking technology for capturing digital X-ray images. This platform technology enables high resolution 3D imaging at low radiation dose to the patient.

» Watch tomosynthesis cine movie

[buystock] 16/1/2010 08:05

RNS Number : 5662D
XCounter AB
03 December 2009

?
PRESS RELEASE




Stockholm, 03 December 2009



XCounter notification of changes in significant shareholdings


XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of
photon counting X-ray detectors and tomosynthesis based 3D medical
imaging, announces it has received notification from Whitehorse Investing Ltd
("Whitehorse") that it has purchased 4,100,000
XCounter shares representing
9.41 % of the issued share capital of XCounter, from HealthCap. The Company has
also received notification that funds managed by HealthCap RNS Number : 5924E
XCounter AB
22 December 2009

PRESS RELEASE




Stockholm, 22 December 2009



XCounter notification of changes in significant shareholdings


XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of
photon counting X-ray detectors and tomosynthesis based 3D medical imaging,
announces today that it has received notification from Whitehorse Investing Ltd
("Whitehorse") that on the 21st December 2009 it purchased 734,786 XCounter
shares taking its total shareholding to 4,834,786 shares which represents 11.1 %
of XCounter.

[buystock] 16/1/2010 07:45

all loading up Changes in significant shareholdings






TIDMXCT

RNS Number : 6760F
XCounter AB
15 January 2010




PRESS RELEASE


Stockholm, 15 January 2010

XCounter notification of changes in significant shareholdings
XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of
photon counting X-ray detectors and tomosynthesis based 3D medical imaging,
announces today that it has received notification from XR Invest AS that it has
purchased 11,818,181 XCounter shares representing 13.05 % of the issued share
capital of XCounter.


Stockholm, 03 December 2009



XCounter notification of changes in significant shareholdings


XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of
photon counting X-ray detectors and tomosynthesis based 3D medical
imaging, announces it has received notification from Whitehorse Investing Ltd
("Whitehorse") that it has purchased 4,100,000
XCounter shares representing
9.41 % of the issued share capital of XCounter, from HealthCap. The Company has
also received notification that funds managed by HealthCap RNS Number : 5924E
XCounter AB
22 December 2009

PRESS RELEASE




Stockholm, 22 December 2009



XCounter notification of changes in significant shareholdings


XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of
photon counting X-ray detectors and tomosynthesis based 3D medical imaging,
announces today that it has received notification from Whitehorse Investing Ltd
("Whitehorse") that on the 21st December 2009 it purchased 734,786 XCounter
shares taking its total shareholding to 4,834,786 shares which represents 11.1 %
of XCounter.

[buystock] 15/1/2010 15:08

15/01/2010 14:51:56 9.00 55,062 O 4,955.58
15/01/2010 10:53:49 9.00 5,417 O 487.53
15/01/2010 10:40:31 9.00 5,555 O 499.95
15/01/2010 10:38:43 9.00 10,000 O 900.00
14/01/2010 12:35:35 8.00 7,307 O 584.56
14/01/2010 12:30:17 8.00 1,875 O 150.00
14/01/2010 12:27:01 8.00 466 O 37.28
14/01/2010 12:18:39 8.00 4,365 O 349.20
14/01/2010 11:48:42 8.00 5,000 O 400.00
14/01/2010 11:48:18 8.00 5,000 O 400.00
14/01/2010 11:22:24 8.00 5,000 O 400.00
14/01/2010 10:53:20 8.00 1,244 O 99